These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20337745)

  • 21. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 23. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada.
    Lebner AC; Beard KM; Soroka SD; Cournoyer SH; Da Roza GA; Geary DF; Mendelssohn DC
    Nephrol Dial Transplant; 2011 Jan; 26(1):156-63. PubMed ID: 20667990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
    Kumar N; Lindberg J; David K; Morris J; Menoyo J
    Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis.
    Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL
    Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465
    [No Abstract]   [Full Text] [Related]  

  • 32. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
    Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
    Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone metabolism according to chronic kidney disease stages in patients undergoing kidney transplantation: a 5-year database analysis.
    Fernández-Fresnedo G; Rodrigo E; Ruiz JC; Martín de Francisco AL; Arias M
    Transplant Proc; 2009; 41(6):2403-5. PubMed ID: 19715933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D deficiency and associated factors in hemodialysis patients.
    Jean G; Charra B; Chazot C
    J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
    Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
    PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.